Products
APN01 is in clinical development at Apeiron Biologics.
Structure and properties
APN01 is a recombinant, soluble, and human angiotensin-converting enzyme 2 (ACE2).
Effects
APN01 functions as a false receptor for the coronavirus SARS-CoV-2, the causative agent of the viral disease Covid-19. SARS-CoV-2 uses ACE2 for attachment and entry into host cells. APN01 is a “decoy” for the virus, so to speak. Furthermore, ACE2 degrades the pro-inflammatory and hypertensive angiotensin II by taking over the function of the endogenous enzyme. The function of ACE2 is limited by viral infection.
Indications
- ARDS (acute respiratory distress syndrome), respiratory failure.
- Pulmonary arterial hypertension (PAH).
- In 2020, APN01 was investigated for the treatment of coronavirus disease Covid-19.
Dosage
According to the professional information. The drug is administered as an intravenous infusion.
